Laboratory of Skin Bioengineering and Imaging, Department of Dermatopathology, University Hospital Sart Tilman, Liège, Belgium.
Eur J Dermatol. 2012 Jan-Feb;22(1):54-7. doi: 10.1684/ejd.2011.1581.
Cancer patients under targeted chemotherapy to the epidermal growth factor receptor (EGFR) frequently suffer from unusual skin adverse events. In the past, these changes were globally qualified as a rash. Our aim was to assess objectively by non invasive bioinstrumentation some early structural and functional skin changes associated with EGFR inhibitor treatment. A series of 27 cancer patients aged 58-66 years were assessed using two ultraviolet light emitting CCD cameras, Visioscan(®) and Visiopor(®). Assessments were performed on the foreheads at inclusion and therefore at weekly intervals for 2 months at most. No topical treatment was applied during the assessment period. The Visioscan(®) camera revealed specular light reflectance at the site of follicular plugging. The interfollicular stratum corneum showed occasional focal hyperkeratosis. These features increased in severity with the EGFR inhibitor treatment, indicating follicular involvement as an early adverse event of the therapy. The follicular fluorescence revealed by the Visiopor(®) camera remained unchanged over the treatment period. The present findings suggest an EGFR inhibitor-induced kerosis (follicular hyperkeratosis) possibly responsible for acneiform reactions.
接受表皮生长因子受体 (EGFR) 靶向化疗的癌症患者经常出现异常皮肤不良反应。过去，这些变化被全球统一归类为皮疹。我们的目的是通过非侵入性生物仪器客观评估与 EGFR 抑制剂治疗相关的一些早期结构和功能皮肤变化。对 27 名年龄在 58-66 岁的癌症患者进行了一系列评估，使用了两个紫外线发射 CCD 摄像机 Visioscan(®)和 Visiopor(®)。评估在纳入时进行额头评估，因此最多在 2 个月内每周进行一次。评估期间不使用任何局部治疗。Visioscan(®)相机揭示了毛囊堵塞部位的镜面光反射。毛囊间角质层偶尔出现局灶性过度角化。这些特征随着 EGFR 抑制剂治疗的加重而加重，表明毛囊受累是治疗的早期不良反应之一。Visiopor(®)相机揭示的毛囊荧光在治疗期间保持不变。目前的研究结果表明，EGFR 抑制剂诱导的角化（毛囊过度角化）可能是痤疮样反应的原因。
